reports
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright B...
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexico...
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results...
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at ...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual ...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medici...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Nov...
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the...
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Heal...
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering m...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Fina...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate m...
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Fi...
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events...
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRE...
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg dose, meeting the Company’s objectives for the study Advancement of 10 mg dose into Phase 3 development in DPNP supported by both PROGRESS and RELIEF DPN-1 studies, which collectively enrolled approximately 600 pilavapadin-treated patients Conference call and webcast at 8:00 a.m. ET THE WOODLANDS, Texas, March 03, 2025...
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROG...
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline results from the Phase 2b PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticE...
Published Data in The Lancet Diabetes & Endocrinology Highlights Uniqu...
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin THE WOODLANDS, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing t...
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Ne...
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025. In advance of topline data from the Phase 2b PROGRESS tri...
Lexicon Appoints Scott Coiante as Chief Financial Officer
Lexicon Appoints Scott Coiante as Chief Financial Officer THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from A...
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (...
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) Confirms Previously Disclosed and Anticipated FDA Decision THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This expected communication from the FDA a...
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study ...
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule Top-line Data Expected in Q1 2025 THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an...
Lexicon Pharmaceuticals to Participate in December Investor Conference...
Lexicon Pharmaceuticals to Participate in December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December. Piper Sandler 36th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET7th Annual Evercore HealthCONx Conference: Presentation Thursday, December 5, 2024 at 12:30 pm ET Simultaneous webcasts will be available in the ...
Lexicon to Reposition as Clinical Development-Focused Company Followin...
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D Pipeline Including Ongoing Studies in DPNP, HCM and Obesity Efforts Expected to Reduce 2025 Operating Costs by $100 Million Conference Call and Webcast at 9:00 am ET THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate ...
Lexicon Appoints Ivan H. Cheung to Board of Directors
Lexicon Appoints Ivan H. Cheung to Board of Directors THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manag...
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Sp...
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association’s (AHA) Sessions 2024 being held Novembe...
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results a...
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP); Topline Data Expected in Q1 2025 Executed Repositioning of INPEFA® (sotagliflozin); Net Sales of $1.7 Million in Q3 2024 Conference Call and Webcast at 5:00pm ET THE WOODLAN...
Lexicon Pharmaceuticals to Participate in the Jefferies London Global ...
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon management including Mike Exton, Lexicon’s chief executive officer and director will participate in a moderated discussion on Wednesday, November 20, 2024, at 9:00 am GT. A simultaneous webcast will be available in the “Events” section of the Lexicon website at , and a recording of the webcast will be available for two weeks follow...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.